Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Fritz, Jason M ^a   Dwyer Nield, Lori D ^a   Malkinson, Alvin M ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cytokines; IGF 1; Lung cancer; Macrophages; Proliferation

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; CYCLIN D1; INTERLEUKIN 4; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; SOMATOMEDIN C; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; LUNG ALVEOLUS CELL; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LUNG CARCINOGENESIS; MALE; MOUSE; NONHUMAN; TREATMENT RESPONSE; TUMOR GROWTH; ADENOMA; ANIMAL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVATION; HUMAN; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; UPREGULATION;

MURINAE; MUS;

ADENOMA; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENZYME ACTIVATION; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LUNG NEOPLASMS; MACROPHAGES, ALVEOLAR; MALE; MAP KINASE KINASE KINASES; MICE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; UP-REGULATION;

EID: 79959434572     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-76     Document Type: Article

References (61)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Schottenfeld D. Epidemiology of Lung Cancer. Lung Cancer: Principles and Practice 1996, 305-321. Philadelphia: Lippincott-Raven Publishers, Pass HI, Mitchell JB, Johnson DH, Turrisi AT.
3. Alberg AJ, Samet JM. Biology of Lung Cancer 1998, 11-52. New York: Marcel Dekker, Inc., Kane MA, Bunn PA.
4. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 2008, 66:208-217. 10.1016/j.critrevonc.2008.01.004, 2483429, 18304833.
5. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett SM. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther 2007, 7:1405-1421. 10.1586/14737140.7.10.1405, 17944566.
6. Redente EF, Orlicky DJ, Bouchard RJ, Malkinson AM. Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice. Am J Pathol 2007, 170:693-708. 10.2353/ajpath.2007.060566, 1851863, 17255336.
7. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Strom SR, Burdick MD, Iannettoni MD, Strieter RM. Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother 2000, 49:63-70. 10.1007/s002620050603, 10823415.
8. Ballaz S, Mulshine JL. The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer 2003, 5:46-62. 10.3816/CLC.2003.n.021, 14596704.
9. Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS, Jeffrey RR. Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 2000, 27:27-35. 10.1016/S0169-5002(99)00095-1, 10672781.
10. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002, 420:860-867. 10.1038/nature01322, 2803035, 12490959.
11. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006, 177:7303-7311.
12. Bauer AK, Dwyer-Nield LD, Keil K, Koski K, Malkinson AM. Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: a role in tumor promotion. Exp Lung Res 2001, 27:197-216.
13. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266. 10.1016/j.cell.2006.01.007, 16439202.
14. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol 2005, 175:1197-1205.
15. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, Segall JE, Pollard JW, Condeelis J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 2007, 67:2649-2656. 10.1158/0008-5472.CAN-06-1823, 17363585.
16. Guth AM, Janssen WJ, Bosio CM, Crouch EC, Henson PM, Dow SW. Lung environment determines unique phenotype of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2009, 296:L936-L946. 10.1152/ajplung.90625.2008, 2692811, 19304907.
17. Zhong L, Roybal J, Chaerkady R, Zhang W, Choi K, Alvarez CA, Tran H, Creighton CJ, Yan S, Strieter RM, Pandey A, Kurie JM. Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res 2008, 68:7237-7245. 10.1158/0008-5472.CAN-08-1529, 2562343, 18757440.
18. Kimura YN, Watari K, Fotovati A, Hosoi F, Yasumoto K, Izumi H, Kohno K, Umezawa K, Iguchi H, Shirouzu K, Takamori S, Kuwano M, Ono M. Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci 2007, 98:2009-2018. 10.1111/j.1349-7006.2007.00633.x, 17924976.
19. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit DB. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008, 68:9375-9383. 10.1158/0008-5472.CAN-08-2223, 2649746, 19010912.
20. Rice PL, Barrett BS, Fritz JM, Srebernak MC, Kisley LR, Malkinson AM, Dwyer-Nield LD. Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal-regulated kinase 1/2 in lung epithelial cells. Exp Lung Res 2010, 36:558-571. 10.3109/01902148.2010.491891, 20815659.
21. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, Miller VA, Ladanyi M. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008, 14:5731-5734. 10.1158/1078-0432.CCR-08-0646, 2754127, 18794081.
22. Fritz JM, Dwyer-Nield LD, Russell BM, Malkinson AM. The Kras mutational spectra of chemically induced lung tumors in different inbred mice mimics the spectra of KRAS mutations in adenocarcinomas in smokers versus nonsmokers. J Thorac Oncol 2010, 5:254-257. 10.1097/JTO.0b013e3181c8ce04, 3095832, 20101149.
23. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000, 351(Pt 2):289-305. 1221363, 11023813.
24. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008, 14:1351-1356. 10.1038/nm.1890, 2683415, 19029981.
25. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001, 410:1111-1116. 10.1038/35074129, 11323676.
26. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928. 10.1038/nrc2536, 19029956.
27. Dziadziuszko R, Camidge DR, Hirsch FR. The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 2008, 3:815-818. 10.1097/JTO.0b013e31818180f5, 18670298.
28. Bitterman PB, Rennard SI, Hunninghake GW, Crystal RG. Human alveolar macrophage growth factor for fibroblasts. Regulation and partial characterization. J Clin Invest 1982, 70:806-822. 10.1172/JCI110677, 370289, 7119116.
29. Rom WN, Basset P, Fells GA, Nukiwa T, Trapnell BC, Crysal RG. Alveolar macrophages release an insulin-like growth factor I-type molecule. J Clin Invest 1988, 82:1685-1693. 10.1172/JCI113781, 442738, 3183063.
30. Olbruck H, Seemayer NH, Voss B, Wilhelm M. Supernatants from quartz dust treated human macrophages stimulate cell proliferation of different human lung cells as well as collagen-synthesis of human diploid lung fibroblasts in vitro. Toxicol Lett 1998, 96-97:85-95. 10.1016/S0378-4274(98)00054-X, 9820652.
31. Finkelstein JN, O'Reilly MA, Holm BA, Chess PR, Notter RH. Cell and animal models of lung injury. Lung injury. Mechanisms, Pathophysiology, and Therapy 2005, 353-404. Philadelphia: Taylor and Francis, Notter RH, Finkelstein JN, Holm BA.
32. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999, 286:1741-1744. 10.1126/science.286.5445.1741, 10576742.
33. Light Y, Paterson H, Marais R. 14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity. Mol Cell Biol 2002, 22:4984-4996. 10.1128/MCB.22.14.4984-4996.2002, 139778, 12077328.
34. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22. 10.1038/nrc969, 12509763.
35. Lim KH, Counter CM. Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. Cancer Cell 2005, 8:381-392. 10.1016/j.ccr.2005.10.014, 16286246.
36. David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, Brody AR. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 2004, 10:6865-6871. 10.1158/1078-0432.CCR-04-0174, 15501963.
37. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, Nilsson UJ, Haslett C, Forbes SJ, Sethi T. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008, 180:2650-2658.
38. Redente EF, Dwyer-Nield LD, Merrick DT, Raina K, Agarwal R, Pao W, Rice PL, Shroyer KR, Malkinson AM. Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol 2010, 176:2972-2985. 10.2353/ajpath.2010.090879, 2877857, 20431028.
39. Wynes MW, Frankel SK, Riches DW. IL-4-induced macrophage-derived IGF-I protects myofibroblasts from apoptosis following growth factor withdrawal. J Leukoc Biol 2004, 76:1019-1027. 10.1189/jlb.0504288, 15316031.
40. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009, 6:201-205. 10.1513/pats.200809-107LC, 19349489.
41. Mamay CL, Schauer IE, Rice PL, Dwyer-Nield LD, You M, Sclafani RA, Malkinson AM. Cyclin D1 as a proliferative marker regulating retinoblastoma phosphorylation in mouse lung epithelial cells. Cancer Lett 2001, 168:165-172. 10.1016/S0304-3835(01)00480-3, 11403921.
42. Hogg JC, van ES. Pulmonary and systemic response to atmospheric pollution. Respirology 2009, 14:336-346. 10.1111/j.1440-1843.2009.01497.x, 19353772.
43. Sabroe I, Parker LC, Dockrell DH, Davies DE, Dower SK, Whyte MK. Targeting the networks that underpin contiguous immunity in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:306-311. 10.1164/rccm.200606-777PP, 17138954.
44. Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, Trivers G, Alberg AJ, Harris CC. Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev 2009, 18:215-222. 10.1158/1055-9965.EPI-08-0705, 2790156, 19124500.
45. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, Markowitz D, Wu W, Liu C, Reisfeld RA, Xiang R. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 2006, 116:2132-2141. 10.1172/JCI27648, 1513049, 16862213.
46. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664. 10.1056/NEJMra030831, 15084698.
47. Raina K, Agarwal R. Combinatorial strategies for cancer eradication by silibinin and cytotoxic agents: efficacy and mechanisms. Acta Pharmacol Sin 2007, 28:1466-1475. 10.1111/j.1745-7254.2007.00691.x, 17723180.
48. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008, 68:8322-8332. 10.1158/0008-5472.CAN-07-6720, 18922904.
49. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. J Immunol 2005, 175:342-349.
50. Zerbe LK, Dwyer-Nield LD, Fritz JM, Redente EF, Shroyer RJ, Conklin E, Kane S, Tucker C, Eckhardt SG, Gustafson DL, Iwata KK, Malkinson AM. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer Chemother Pharmacol 2008, 62:605-620. 10.1007/s00280-007-0644-z, 18030469.
51. Dwyer-Nield LD, Srebernak MC, Barrett BS, Ahn J, Cosper P, Meyer AM, Kisley LR, Bauer AK, Thompson DC, Malkinson AM. Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic vs. non-tumorigenic mouse lung epithelial cell lines. Carcinogenesis 2005, 26:1196-1206.
52. van der Heijden MS, Bernards R. Inhibition of the PI3K pathway: hope we can believe in?. Clin Cancer Res 2010, 16:3094-3099. 10.1158/1078-0432.CCR-09-3004, 20400520.
53. Frye SV, Johnson GL. Inhibitors paradoxically prime kinases. Nat Chem Biol 2009, 5:448-449. 10.1038/nchembio.f.11, 19465930.
54. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 1997, 272:4378-4383. 10.1074/jbc.272.7.4378, 9020159.
55. Malkinson AM, Beer DS. Major effect on susceptibility to urethan-induced pulmonary adenoma by a single gene in BALB/cBy mice. J Natl Cancer Inst 1983, 70:931-936.
56. Chichester CH, Philpot RM, Weir AJ, Buckpitt AR, Plopper CG. Characterization of the cytochrome P-450 monooxygenase system in nonciliated bronchiolar epithelial (Clara) cells isolated from mouse lung. Am J Respir Cell Mol Biol 1991, 4:179-186.
57. Malkinson AM, Dwyer-Nield LD, Rice PL, Dinsdale D. Mouse lung epithelial cell lines-tools for the study of differentiation and the neoplastic phenotype. Toxicology 1997, 123:53-100. 10.1016/S0300-483X(97)00108-X, 9347924.
58. Mbawuike IN, Herscowitz HB. MH-S, a murine alveolar macrophage cell line: morphological, cytochemical, and functional characteristics. J Leukoc Biol 1989, 46:119-127.
59. Cumming G, Fidler F, Vaux DL. Error bars in experimental biology. J Cell Biol 2007, 177:7-11. 10.1083/jcb.200611141, 2064100, 17420288.
60. Curran-Everett D. Multiple comparisons: philosophies and illustrations. Am J Physiol Regul Integr Comp Physiol 2000, 279:R1-R8.
61. Curran-Everett D, Benos DJ. Guidelines for reporting statistics in journals published by the American Physiological Society. Am J Physiol Regul Integr Comp Physiol 2004, 287:R247-R249. 10.1152/ajpregu.00346.2004, 15789454.